Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics cash
Cash and short-term investments held at the end of each period.
Sangamo Therapeutics's cash was $27.59M at Mar 31, 2026. For fiscal 2025 it was $20.95M, down 50.0% from the year before. Over ten years it grew -11.3% a year on average. The highest annual figure on record is $642.92M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.95M | -50.0% |
| FY2024 | Dec 31, 2024 | $41.92M | -48.2% |
| FY2023 | Dec 31, 2023 | $81.00M | -73.7% |
| FY2022 | Dec 31, 2022 | $307.50M | -18.7% |
| FY2021 | Dec 31, 2021 | $378.05M | -41.2% |
| FY2020 | Dec 31, 2020 | $642.92M | +76.6% |
| FY2019 | Dec 31, 2019 | $363.97M | -9.8% |
| FY2018 | Dec 31, 2018 | $403.63M | +63.5% |
| FY2017 | Dec 31, 2017 | $246.81M | +1018.8% |
| FY2016 | Dec 31, 2016 | $22.06M | -68.2% |
| FY2015 | Dec 31, 2015 | $69.48M | +1052.3% |
| FY2014 | Dec 31, 2014 | $6.03M | -93.5% |
| FY2013 | Dec 31, 2013 | $92.81M | +46.1% |
| FY2012 | Dec 31, 2012 | $63.55M | -24.5% |
| FY2011 | Dec 31, 2011 | $84.13M | +39.6% |
| FY2010 | Dec 31, 2010 | $60.29M | +184.9% |
| FY2009 | Dec 31, 2009 | $21.16M | +9.0% |
| FY2008 | Dec 31, 2008 | $19.41M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $27.59M | +9.6% |
| Q4 FY2025 | Dec 31, 2025 | $20.95M | -50.0% |
| Q3 FY2025 | Sep 30, 2025 | $29.62M | -24.5% |
| Q2 FY2025 | Jun 30, 2025 | $38.34M | +38.0% |
| Q1 FY2025 | Mar 31, 2025 | $25.18M | -53.7% |
| Q4 FY2024 | Dec 31, 2024 | $41.92M | -48.2% |
| Q3 FY2024 | Sep 30, 2024 | $39.20M | -70.3% |
| Q2 FY2024 | Jun 30, 2024 | $27.79M | -84.7% |
| Q1 FY2024 | Mar 31, 2024 | $54.42M | -77.4% |
| Q4 FY2023 | Dec 31, 2023 | $81.00M | -73.7% |
| Q3 FY2023 | Sep 30, 2023 | $132.10M | -57.9% |
| Q2 FY2023 | Jun 30, 2023 | $182.10M | -42.3% |
| Q1 FY2023 | Mar 31, 2023 | $241.00M | -24.2% |
| Q4 FY2022 | Dec 31, 2022 | $307.50M | -18.7% |
| Q3 FY2022 | Sep 30, 2022 | $313.57M | -25.9% |
| Q2 FY2022 | Jun 30, 2022 | $315.72M | -40.4% |
| Q1 FY2022 | Mar 31, 2022 | $317.80M | -45.9% |
| Q4 FY2021 | Dec 31, 2021 | $378.05M | -41.2% |
| Q3 FY2021 | Sep 30, 2021 | $423.41M | -34.7% |
| Q2 FY2021 | Jun 30, 2021 | $529.65M | -20.3% |
| Q1 FY2021 | Mar 31, 2021 | $587.08M | +63.9% |
| Q4 FY2020 | Dec 31, 2020 | $642.92M | +76.6% |
| Q3 FY2020 | Sep 30, 2020 | $648.83M | +82.8% |
| Q2 FY2020 | Jun 30, 2020 | $664.85M | +50.7% |
| Q1 FY2020 | Mar 31, 2020 | $358.13M | +2.0% |
| Q4 FY2019 | Dec 31, 2019 | $363.97M | -9.8% |
| Q3 FY2019 | Sep 30, 2019 | $354.85M | -22.6% |
| Q2 FY2019 | Jun 30, 2019 | $441.10M | -18.2% |
| Q1 FY2019 | Mar 31, 2019 | $351.00M | +1043.0% |
| Q4 FY2018 | Dec 31, 2018 | $403.63M | +63.5% |
| Q3 FY2018 | Sep 30, 2018 | $458.57M | +1434.0% |
| Q2 FY2018 | Jun 30, 2018 | $539.45M | +672.4% |
| Q1 FY2018 | Mar 31, 2018 | $30.71M | +66.1% |
| Q4 FY2017 | Dec 31, 2017 | $246.81M | +1018.8% |
| Q3 FY2017 | Sep 30, 2017 | $29.89M | +6.8% |
| Q2 FY2017 | Jun 30, 2017 | $69.84M | +439.1% |
| Q1 FY2017 | Mar 31, 2017 | $18.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.06M | – |
| Q3 FY2016 | Sep 30, 2016 | $27.99M | – |
| Q2 FY2016 | Jun 30, 2016 | $12.96M | – |
See a number that looks wrong?